GU Cancers Symposium 2014 - Results from #40

GU Cancers Symposium 2014 - Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma - Session Highlights February 3, 2014

GU Cancers Symposium 2014 - Results of the MARS study on the management of antiangiogenics’ renovascular safety in renal cell carcinoma - Session Highlights February 3, 2014

GU Cancers Symposium 2014 - SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer - Session Highlights February 3, 2014

GU Cancers Symposium 2014 - The evolving indications for renal biopsy - Session Highlights February 3, 2014

GU Cancers Symposium 2014 - Tumor heterogeneity and systemic therapy: Now what? - Session Highlights February 3, 2014

GU Cancers Symposium 2014 - Models, nomograms, biomarkers, and risk: Can we measure heterogeneity for clinical benefit and decision making? - Session Highlights February 3, 2014

GU Cancers Symposium 2014 - Heterogeneity and the renal mass biopsy: Its role and reliability - Session Highlights February 3, 2014

GU Cancers Symposium 2014 - Intratumoral heterogeneity and branched evolution: Implications and future directions - Session Highlights February 3, 2014

GU Cancers Symposium 2014 - Best of journals: Renal cancer - Session Highlights February 3, 2014

GU Cancers Symposium 2014 - Best of journals: Renal cancer – translational research - Session Highlights February 3, 2014

GU Cancers Symposium 2014 - Best of journals: Renal cancer - medical oncology - Session Highlights February 3, 2014

GU Cancers Symposium 2014 - Craniocaudal retroperitoneal node length as a risk factor for relapse from clinical stage I testicular germ cell tumor - Session Highlights February 3, 2014

GU Cancers Symposium 2014 - Is high-dose chemotherapy plus stem-cell transplant the standard treatment for patients for whom first-line chemotherapy for metastatic germ cell tumor failed? - Session Highlights February 3, 2014

GU Cancers Symposium 2014 - Is early-chemotherapy switch the standard treatment for poor-risk metastatic disease and slow tumor marker decline? - Session Highlights February 3, 2014

GU Cancers Symposium 2014 - Is surveillance the standard treatment for clinical stage I germ cell tumor? - Session Highlights February 3, 2014

GU Cancers Symposium 2014 - A decade in review: Building blocks in the progress in management of urothelial carcinomas - Session Highlights February 3, 2014

GU Cancers Symposium 2014 - A decade in review: Penile, urethral, and testicular cancers - Session Highlights February 3, 2014

GU Cancers Symposium 2014 - Patterns of relapse in poor-prognosis germ cell tumors in the GETUG 13 trial: Implications for assessment of brain progression - Session Highlights February 3, 2014

GU Cancers Symposium 2014 - Multicenter sequential phase II study of flavopiridol plus oxaliplatin (alvocidib) with or without 5-FU and leucovorin for patients with refractory germ cell tumors including late relapse - Session Highlights February 3, 2014

GU Cancers Symposium 2014 - Premature termination of genitourinary cancer clinical trials - Session Highlights February 3, 2014

Page 3 of 6